Eye care collaboration for AbbVie and REGENXBIO

AbbVie and REGENXBIO have partnered to develop and commercialise RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.

RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilising subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilising in-office suprachoroidal delivery.

Under the collaboration, REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials.

AbbVie will lead the clinical development and commercialisation of RGX-314 globally. REGENXBIO shall participate in US commercialisation efforts as provided under a mutually agreed upon commercialization plan.

“AbbVie is a strong, complementary partner for REGENXBIO. We expect to leverage AbbVie’s global developmental and commercial infrastructure within eye care with our expertise in AAV gene therapy clinical development and deep in-house knowledge of manufacturing and production to continue the development of RGX-314,” said Kenneth T. Mills, president and chief executive officer of REGENXBIO.

AbbVie will pay REGENXBIO a $370 million upfront payment with the potential for REGENXBIO to receive up to $1.38 billion in additional development, regulatory and commercial milestones.

REGENXBIO and AbbVie will share equally in profits from net sales of RGX-314 in the US AbbVie will pay REGENXBIO tiered royalties on net sales of RGX-314 outside the US.

In addition, REGENXBIO will lead the manufacturing of RGX-314 for clinical development and US commercial supply, and AbbVie will lead manufacturing of RGX-314 for commercial supply outside the US.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news